Compare Abbott Laboratories (ABT) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Vanguard S&P 500 ETF — how do they compare? Abbott Laboratories trades at $109.64 (market cap $187.95B), while Vanguard S&P 500 ETF trades at $710.05. The key difference: Abbott Laboratories pays a 2.32% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | VOO | |
|---|---|---|
Market Cap | $187.95B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $710.71 |
52-Week Low | $82.57 | $580.93 |
Enterprise Value | $214.96B | — |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
VOO trades at $710.12, down slightly by 0.07% amid mixed market signals. Technical indicators show a bullish trend with strong moving average support, though oscillators suggest caution with RSI levels indicating overbought conditions. The ETF remains a core holding for broad US market exposure, with institutional interest demonstrated by recent position increases from advisory firms.
The outlook for VOO remains positive given its low-cost S&P 500 exposure, though current market valuations present near-term risk. Key catalysts include corporate earnings growth and inflation data, while risks center on market breadth concerns and potential profit-taking at record highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
